MedTrace Logo

A Single-Center, Phase 2 Study Evaluating Bilastine Ophthalmic Solution in the CAC® Model

NCT03231969 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2023-03-16

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of Bilastine Ophthalmic Solution (0.2%,0.4%,0.6%) compared to vehicle for the treatment of the signs and symptoms of allergic conjunctivitis

Conditions

  • Allergic Conjunctivitis

Interventions

DRUG

Bilastine 0.2%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0.4%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0.6%

1 drop in each eye at 3 separate times during a 25 day period.

DRUG

Bilastine 0%

1 drop in each eye at 3 separate times during a 25 day period.

Sponsors & Collaborators

  • ORA, Inc.

    collaborator INDUSTRY

  • Faes Farma, S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2017-10-11
Completion
2017-10-11
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03231969 on ClinicalTrials.gov